{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-25-000008","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.842665+00:00","generated_at":"2026-05-25T04:49:08.568737+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lexicon reports Q4 net loss $33.8M; pilavapadin 10mg advances to Phase 3","bullets":["Q4 net loss $33.8M ($0.09/shr) vs $49.8M loss in Q4 2023; revenue $26.6M including $25M Viatris upfront.","Phase 2b PROGRESS study of pilavapadin met objectives; 10mg dose showed meaningful pain reduction vs placebo; Phase 3 targeting 2025.","Cash and investments $238.0M at Dec 31, 2024, up from $170.0M year-end 2023; full-year net loss $200.4M.","Company ceased active INPEFA promotion and discontinued Zynquista launch prep after FDA CRL; leaner R&D-focused organization.","LX9851 IND on track for 2025; sotagliflozin Phase 3 SONATA HCM trial enrolling with 500-patient target."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-25-000008","json":"https://secwatch.observer/filing/0001062822-25-000008.json","markdown":"https://secwatch.observer/filing/0001062822-25-000008.md","text":"https://secwatch.observer/filing/0001062822-25-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282225000008/0001062822-25-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282225000008/lxrx-20250306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T04:49:08.568737+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}